
Francesco Rubino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1715899/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Consensus report: Definition and interpretation of remission in type 2 diabetes. Diabetic Medicine, 2022, 39, e14669.	1.2	15
2	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1-9.	1.8	32
3	The effect of COVID-19 on routine diabetes care and mortality in people with diabetes. Lancet Diabetes and Endocrinology,the, 2022, 10, 550-551.	5.5	2
4	The Effect of Standard Versus Longer Intestinal Bypass on GLP-1 Regulation and Glucose Metabolism in Patients With Type 2 Diabetes Undergoing Roux-en-Y Gastric Bypass: The Long-Limb Study. Diabetes Care, 2021, 44, 1082-1090.	4.3	14
5	Returning to Surgery—Experience, Discussions and Consensus. Obesity Surgery, 2021, 31, 1336-1338.	1.1	2
6	Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet, The, 2021, 397, 293-304.	6.3	272
7	Long limb compared with standard limb Roux-en-Y gastric bypass for type 2 diabetes and obesity: the LONG LIMB RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-54.	0.9	7
8	Consequences of the COVID-19 pandemic for patients with metabolic diseases. Nature Metabolism, 2021, 3, 289-292.	5.1	33
9	Obesity: what's in a word?. Lancet Diabetes and Endocrinology,the, 2021, 9, 408-409.	5.5	2
10	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care, 2021, 44, 2438-2444.	4.3	152
11	Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia, 2021, 64, 2359-2366.	2.9	39
12	COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes and Endocrinology,the, 2021, 9, 786-798.	5.5	155
13	Management of diabetes in patients with COVID-19 – Authors' reply. Lancet Diabetes and Endocrinology,the, 2020, 8, 669-670.	5.5	14
14	Bariatric and metabolic surgery during and after the COVID-19 pandemic – Authors' reply. Lancet Diabetes and Endocrinology,the, 2020, 8, 743-744.	5.5	1
15	Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. Lancet Diabetes and Endocrinology,the, 2020, 8, 640-648.	5.5	139
16	New-Onset Diabetes in Covid-19. New England Journal of Medicine, 2020, 383, 789-790.	13.9	624
17	Knowledge gaps and weight stigma shape attitudes toward obesity. Lancet Diabetes and Endocrinology,the, 2020, 8, 363-365.	5.5	27
18	Male Obesity Associated Gonadal Dysfunction and the Role of Bariatric Surgery. Frontiers in Endocrinology, 2020, 11, 408.	1.5	19

FRANCESCO RUBINO

#	Article	IF	CITATIONS
19	Diabetes, obesity and <scp>COVID</scp> â€19: A complex interplay. Diabetes, Obesity and Metabolism, 2020, 22, 1892-1896.	2.2	51
20	Joint international consensus statement for ending stigma of obesity. Nature Medicine, 2020, 26, 485-497.	15.2	468
21	Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes and Endocrinology,the, 2020, 8, 546-550.	5.5	680
22	Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?. Metabolism: Clinical and Experimental, 2019, 100, 153960.	1,5	16
23	Metabolic Surgery. Journal of the American College of Cardiology, 2018, 71, 670-687.	1.2	130
24	Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia, 2018, 61, 257-264.	2.9	134
25	Metabolic surgery: the cutting edge of diabetes care. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 389-390.	8.2	5
26	Response to Comment on Gastaldelli et al. Short-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass. Diabetes Care 2016;39:1925–1931. Diabetes Care, 2017, 40, e50-e50.	4.3	0
27	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations. Obesity Surgery, 2017, 27, 2-21.	1.1	118
28	Downregulation of Insulin Sensitivity After Oral Glucose Administration: Evidence for the Anti-Incretin Effect. Diabetes, 2017, 66, 2756-2763.	0.3	24
29	Roux-en-Y Gastric Bypass Surgery in the Management of Familial Partial Lipodystrophy Type 1. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3616-3620.	1.8	16
30	The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study. Surgery for Obesity and Related Diseases, 2017, 13, 491-500.	1.0	153
31	Metabolic surgery for treating type 2 diabetes mellitus: Now supported by the world's leading diabetes organizations. Cleveland Clinic Journal of Medicine, 2017, 84, S47-S56.	0.6	31
32	Medical research: Time to think differently about diabetes. Nature, 2016, 533, 459-461.	13.7	25
33	Response to Comment on Rubino et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care 2016;39:861–877. Diabetes Care, 2016, 39, e202-e203.	4.3	18
34	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care, 2016, 39, 861-877.	4.3	718
35	Short-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass. Diabetes Care, 2016, 39, 1925-1931.	4.3	35
36	Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study. Diabetes Care, 2016, 39, 2254-2261.	4.3	171

FRANCESCO RUBINO

#	Article	IF	CITATIONS
37	Obesity, Type 2 Diabetes, and the Metabolic Syndrome. Surgical Clinics of North America, 2016, 96, 681-701.	0.5	31
38	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Surgery for Obesity and Related Diseases, 2016, 12, 1144-1162.	1.0	126
39	Identifying Barriers to Appropriate Use of Metabolic/Bariatric Surgery for Type 2 Diabetes Treatment: Policy Lab Results. Diabetes Care, 2016, 39, 954-963.	4.3	34
40	What is the Mechanism Behind Weight Loss Maintenance with Gastric Bypass?. Current Obesity Reports, 2015, 4, 262-268.	3.5	36
41	Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet, The, 2015, 386, 964-973.	6.3	998
42	Diabetes Surgery. , 2015, , 81-97.		0
43	Refractory Hyperglycemia After Gastric Bypass Surgery: A Novel Subtype of Type 2 Diabetes?. Diabetes Care, 2014, 37, e254-e255.	4.3	8
44	Is the Gut the \hat{a} €œSweet Spot \hat{a} €•for the Treatment of Diabetes?. Diabetes, 2014, 63, 2225-2228.	0.3	33
45	Bariatric, Metabolic, and Diabetes Surgery. Annals of Surgery, 2014, 259, 117-122.	2.1	65
46	Duodenal-Jejunal Bypass and Jejunectomy Improve Insulin Sensitivity in Goto-Kakizaki Diabetic Rats Without Changes in Incretins or Insulin Secretion. Diabetes, 2014, 63, 1069-1078.	0.3	51
47	Surgical control of obesity and diabetes: The role of intestinal vs. gastric mechanisms in the regulation of body weight and glucose homeostasis. Obesity, 2014, 22, 159-169.	1.5	40
48	From Bariatric to Metabolic Surgery: Definition of a New Discipline and Implications for Clinical Practice. Current Atherosclerosis Reports, 2013, 15, 369.	2.0	32
49	Insulin Sensitivity and Secretion Changes After Gastric Bypass in Normotolerant and Diabetic Obese Subjects. Annals of Surgery, 2013, 257, 462-468.	2.1	66
50	The coming of age of metabolic surgery. Nature Reviews Endocrinology, 2012, 8, 702-704.	4.3	24
51	Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes. New England Journal of Medicine, 2012, 366, 1577-1585.	13.9	1,617
52	Duodenal-jejunal bypass protects GK rats from β-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E923-E932.	1.8	91
53	IDF's view of bariatric surgery in type 2 diabetes. Lancet, The, 2011, 378, 108-110.	6.3	48
54	The Diabetes Surgery Summit Consensus Conference. Annals of Surgery, 2010, 251, 399-405.	2.1	298

FRANCESCO RUBINO

#	Article	IF	CITATIONS
55	Metabolic Surgery to Treat Type 2 Diabetes: Clinical Outcomes and Mechanisms of Action. Annual Review of Medicine, 2010, 61, 393-411.	5.0	350
56	How Do We Define Cure of Diabetes?. Diabetes Care, 2009, 32, 2133-2135.	4.3	852
57	Is Type 2 Diabetes an Operable Intestinal Disease?. Diabetes Care, 2008, 31, S290-S296.	4.3	215
58	Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22–34 kg/m2: a report of 2 cases. Surgery for Obesity and Related Diseases, 2007, 3, 195-197.	1.0	200
59	The Mechanism of Diabetes Control After Gastrointestinal Bypass Surgery Reveals a Role of the Proximal Small Intestine in the Pathophysiology of Type 2 Diabetes. Annals of Surgery, 2006, 244, 741-749.	2.1	782
60	The Early Effect of the Roux-en-Y Gastric Bypass on Hormones Involved in Body Weight Regulation and Glucose Metabolism. Annals of Surgery, 2004, 240, 236-242.	2.1	552
61	Effect of Duodenal–Jejunal Exclusion in a Non-obese Animal Model of Type 2 Diabetes. Annals of Surgery, 2004, 239, 1-11.	2.1	581
62	Potential of Surgery for Curing Type 2 Diabetes Mellitus. Annals of Surgery, 2002, 236, 554-559.	2.1	315